AVITA Medical Shares Climb On Topline Results From Soft Tissue Reconstruction Study, Sees PMA Submission By Year-end
AVITA Medical (NASDAQ: RCEL) announced topline results from its pivotal trial evaluating the safety and effectiveness of the RECELL System combined with meshed autograft for reduction of donor skin harvesting in soft tissue reconstruction.